Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q92785
UPID:
REQU_HUMAN
Alternative names:
Apoptosis response zinc finger protein; BRG1-associated factor 45D; D4, zinc and double PHD fingers family 2; Protein requiem
Alternative UPACC:
Q92785; A8K7C9; B4DT58
Background:
Zinc finger protein ubi-d4, also known as Apoptosis response zinc finger protein, BRG1-associated factor 45D, D4, zinc and double PHD fingers family 2, and Protein requiem, plays a pivotal role in transcriptional regulation. It achieves this by binding to modified histones H3 and H4, acting as a negative regulator of myeloid differentiation in hematopoietic progenitor cells, and possibly influencing the development and maturation of lymphoid cells. Additionally, it is involved in the regulation of the non-canonical NF-kappa-B pathway.
Therapeutic significance:
Zinc finger protein ubi-d4 is implicated in Coffin-Siris syndrome 7, a genetic disorder characterized by intellectual disability, coarse facial features, and other systemic malformations. Understanding the role of Zinc finger protein ubi-d4 could open doors to potential therapeutic strategies for this syndrome.